SYNERGY(300636.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
SYNERGY
300636.SZ
Jiangxi Synergy Pharmaceutical Co., Ltd. engages in research and development, production, and sales of chemical raw materials and pharmaceutical intermediates in China and internationally. The company offers nervous system drugs, digestive system medications, antipyretic analgesics and non-steroidal anti-inflammatory analgesics, antihypertensive drugs, anticoagulants, hypoglycemic drugs, antidepressants, as well as antigout and urinary system medications. It also exports its products to Europe, the United States, Japan, South Korea, and other regions.
2.788 T
300636.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking157/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.02%C
    • Profit Margin8.60%B
    • Gross Margin28.55%C
  • Growth ScoreC
    • Revenue YoY11.74%B
    • Net Profit YoY-15.17%D
    • Total Assets YoY-3.21%D
    • Net Assets YoY2.34%C
  • Cash ScoreB
    • Cash Flow Margin265.68%A
    • OCF YoY11.74%B
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreB
    • Gearing Ratio28.01%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SYNERGY passed the on-site inspection by the U.S. FDA

    Zhitong·
    SZ
    300636
    -1.50%
    Zhitong·
    SZ
    300636
    -1.50%

    SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate

    Zhitong·
    SZ
    300636
    -1.50%
    Zhitong·
    SZ
    300636
    -1.50%

    SYNERGY: CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028

    Zhitong·
    SZ
    300636
    -1.50%
    Zhitong·
    SZ
    300636
    -1.50%

    SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection

    Zhitong·
    SZ
    300636
    -1.50%
    Zhitong·
    SZ
    300636
    -1.50%

    SYNERGY: Agomelatine and Opicapone have obtained drug registration certificates in South Korea

    Zhitong·
    SZ
    300636
    -1.50%
    Zhitong·
    SZ
    300636
    -1.50%
    © 2026 Longbridge｜Disclaimer